Bayer Aktiengesellschaft

Manfred Bucheler

Roland Rupp

Josef Schmoll

Bernd Klinksiek

Andreas Ohm

Hans Gehringer

Bernd Koglin

Hans Uhlemann

Helmut Luchtenberg

Norbert Pollinger

Johannes Michaelis

Klaus Benke

Karl H Buchel

Manfred Plempel

Erik Regel

Hildegard Schnoring

Wolfgang Gau

Takaaki Nishioka

Axel Wollenschlager

Eduard Porges

Hans-Jurgen Ploschke

Heinrich Feltkamp

The invention relates to flavor-masked pharmaceutical compositions for oral administration, their preparation and their use as medicaments. The new pharmaceutical preparations according to the invention make it possible to administer pharmaceutical active substances having very unpleasant organoleptic properties such as, for example, very bad taste, even in liquid form.

Flavor-masked pharmaceutical compositions

A process for the continuous fluidized bed agglomeration of a solid in powder form, wherein the powder, a granulating liquid and propelling air are fed through a three-substance nozzle into the center of a fluidized bed to form a three-phase mixture in the center of the fluidized bed.

Process for continuous fluidized bed agglomeration

The invention relates to flavour-masked pharmaceutical compositions for oral administration, their preparation and their use as medicaments. The new pharmaceutical preparations according to the invention make it possible to administer pharmaceutical active substances having very unpleasant organoleptic properties such as, for example, very bad taste, even in liquid form.

Process for the continuous fluidized bed agglomeration wherein the granulating liquid together with propellant air is supplied centrally through a three-phase nozzle on the distributor of the fluidized bed, and at the same time, the solid in powder form is fed into the fluidized bed through the annular space or the three-phase nozzle with the air of a current of propellant air, supplied separately and concentrically.

Apparatus for continuous fluidized bed agglomeration

Controlled release medicament pellets comprising

Medicaments having controlled release of the active compound

The invention relates to a process for the preparation of fine-particled, stable, pharmaceutical or cosmetic dispersions consisting of an aqueous phase and an organic phase which is insoluble or not completely soluble in water (oily phase), in which a pre-emulsion is first prepared from the two phases by known emulsifying methods and is then further processed to the end product. The invention furthermore relates to apparatus for carrying out the process.

Preparation of pharmaceutical or cosmetic dispersions

The invention relates to a process for the preparation of fine-particled, stable, pharmaceutical or cosmetic dispersions consisting of an aqueous phase and an organic phase which is insoluble or not completely soluble in water (oily phase) in which a pre-emulsion is prepared from the two phases by known emulsifying methods and in then pumped through a jet disperser, the temperature, the proportion of the aqueous and organic phases, and the pressure at the jet disperser being adjusted so that phase inversion of the emulsion is effected in the jet disperser at the same time as homogenization and fine dispersion, and in the course of which all the pressure energy is consumed in the dispersing zone and the dispersion leaves as a non-directional stream.

A solid medicament preparation having long-lasting action containing a sparingly soluble dihydropyridine active compound of the Formula (I) ##STR1## the preparation having a core-coating construction, the core containing at least one of the above mentioned dihydropyridines in slow-release form, the inner-most coating situated around the core contains no active compound and only dissolves slowly and adjacent to the inner-most coating a rapid release initial dose of the active compound mixed with a polymer.

DHP delayed release preparation

A pharmaceutical formulation tablet with a long-lasting action for 1 to 2 daily doses having a diameter between about 0.5 and 15 mm and comprising

Dihydropyridine depot formulation

The invention relates to antimycotic compositions comprising (1) an antimycotic effective amount of an azole derivative having antimycotic activity, said azole derivative being in the form of particles less than 4.mu. in size, (2) an acid and/or a buffer system consisting of an organic acid and a salt thereof to provide a pH of 3 to 4 or less in aqueous solution and (3) an inert pharmaceutical carrier. Also included in the invention are methods for the short term treatment of vaginal infections utilizing the compositions of the invention.

Azole derivatives antimycotic agents which release the active compounds

The invention relates to a process for preparing fine-particled, stable, pharmaceutical or cosmetic dispersions which comprises dispersing the entire inner phase in 5-40% by volume of outer phase, then adding the remainder of the outer phase, all under predetermined conditions.

Growing community of inventors

Overath, Germany

Manfred Bucheler